EXAS
Exact Sciences Corporation·Healthcare
104.91
0.000%(+0.00)
Market ClosedLast Updated: — ET
52W L: $38.8152W H: $104.98
EXAS NEWS
defenseworld.net
5d ago
96,685 Shares in Exact Sciences Corporation $EXAS Purchased by Capricorn Fund Managers Ltd
Capricorn Fund Managers Ltd acquired a new stake in shares of Exact Sciences Corporation (NASDAQ: EXAS) during the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 96,685 shares of the medical research company's stock, valued at approximately $9,819,000. Exact Sciences makes up about 2.4% of Capricorn Fund
defenseworld.net
Apr 4
Exact Sciences Corporation $EXAS Shares Sold by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC cut its stake in Exact Sciences Corporation (NASDAQ: EXAS) by 39.6% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,044 shares of the medical research company's stock after selling 5,932 shares during the quarter. Exchange
defenseworld.net
Apr 3
FNY Investment Advisers LLC Buys Shares of 28,500 Exact Sciences Corporation $EXAS
FNY Investment Advisers LLC acquired a new position in shares of Exact Sciences Corporation (NASDAQ: EXAS) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 28,500 shares of the medical research company's stock, valued at approximately $2,894,000. Exact Sciences accounts for about
defenseworld.net
Apr 3
Banque Pictet & Cie SA Lowers Position in Exact Sciences Corporation $EXAS
Banque Pictet and Cie SA decreased its stake in Exact Sciences Corporation (NASDAQ: EXAS) by 77.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,415 shares of the medical research company's stock after selling 151,772 shares
businesswire.com
Mar 17
Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting new data in molecular residual disease (MRD) testing and multi-cancer early detection (MCED). The meeting will take place from April 17–22, 2026, in San Diego, CA. Exact Sciences will present new findings from the NSABP B-59/GBG-96-GeparDouze tri.
defenseworld.net
Mar 16
Bridgefront Capital LLC Buys Shares of 11,994 Exact Sciences Corporation $EXAS
Bridgefront Capital LLC bought a new position in Exact Sciences Corporation (NASDAQ: EXAS) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor bought 11,994 shares of the medical research company's stock, valued at approximately $656,000. Several other institutional investors have also recently made changes to their
